Venoclara impurity reference substance as well as preparation and detection methods thereof

By preparing and detecting new impurity (I) compounds of Vinecla and using high-performance liquid chromatography gradient method, the problem of incomplete impurity control in the prior art has been solved, and the product purity and the effectiveness of quality control have been improved.

CN119019424APending Publication Date: 2024-11-26ABYDOS PHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310598183.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-25
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The lack of comprehensive quality control methods in the existing technology for impurities that may be generated during the Veneclare synthesis process and storage makes it difficult to guarantee product purity and quality.

Method used

A novel impurity compound (I) is prepared, and its preparation method and high-performance liquid chromatography gradient method are provided for impurity detection to ensure complete separation of impurities from the main peak, thereby achieving rapid, simple and reliable impurity control.

Benefits of technology

This enables rapid, simple, and reliable impurity control of Venekel products, improving the purity and overall quality control of the products.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure BDA0004248648360000011
    Figure BDA0004248648360000011
Patent Text Reader

Abstract

The invention discloses an impurity reference substance compound shown as a formula (I) of Venoclara as well as a preparation method and a detection method of the impurity reference substance compound. The preparation method comprises the following steps: reacting a compound shown as a formula (II) with a compound shown as a formula (III) in the presence of a proper solvent and alkali to obtain the compound shown as the formula (I). The invention also discloses a detection method of the impurity, and the method provided by the invention can effectively elute the impurity, so that the peak of the impurity is completely separated from the main peak, and the rapid and reliable impurity control can be carried out on the Venoclara product.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of chemical drug analysis and drug synthesis, and specifically relates to a venetoclax impurity reference substance and a preparation and detection method thereof. Background Art

[0002] Venetoclax (Venetoclax), CAS registration number: 1257044-40-8, chemical name: 2-((1H-pyrrolo[2,3-B]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide, its structural formula is:

[0003]

[0004] Venetoclax was approved by the FDA on April 11, 2016. It is the first BCL-2 inhibitor approved by the US FDA and is currently approved by the US FDA for the treatment of the following diseases:

[0005] 1. Chronic lymphocytic leukemia (CLL) with abnormal chromosome 17p deletion;

[0006] 2. Combined with rituximab as second-line treatment for chronic lymphocytic leukemia / small lymphocytic lymphoma (SLL);

[0007] 3. Combined with azacitidine / decitabine / cytarabine as first-line treatment for acute myeloid leukemia that is not suitable for standard induction therapy.

[0008] Venetoclax is the world's first BCL-2 (B lymphocytoma-2 gene) inhibitor, a selective anti-apoptotic protein and an orally bioavailable small molecule inhibitor. It has significant activity in chronic lymphocytic leukemia and was initially approved by the FDA for chromosome 17p deletion or relapsed / refractory chronic lymphocytic leukemia (CLL). Currently, Venetoclax has been marketed in more than 50 countries / regions around the world.

[0009] Venetoclax has cytotoxic activity in tumor cells that overexpress BCL-2. Venetoclax selectively inhibits the anti-apoptotic protein BCL-2, which is overexpressed in chronic lymphocytic leukemia (CLL) cells and acute myeloid leukemia (AML) cells. BCL-2 mediates tumor cell survival and is associated with chemotherapy resistance. Venetoclax directly binds to the BCL-2 protein, displacing pro-apoptotic proteins and restoring the apoptotic process.

[0010] The original patent reported the synthesis method of venetoclax, which uses 1-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-diphenyl]-2-yl)methyl)piperazine and 4-halogeno-2-(1H-pyrrolo[2,3-B]pyridin-5-yloxy)benzoic acid tert-butyl ester as starting materials, and venetoclax is obtained through substitution, hydrolysis, and condensation reactions. The synthesis route is as follows:

[0011]

[0012] Although some impurities of venetoclax have been reported in existing literature and data, further research on other impurities that may be produced in the synthesis process of venetoclax or in the subsequent preparation and storage processes will help improve the overall quality control of venetoclax and is of great significance. Summary of the invention

[0013] First, the present invention provides an impurity compound of formula (I), which has a chemical structure as shown in the following formula (I):

[0014]

[0015] Secondly, the present invention also provides a method for preparing the impurity compound of formula (I), comprising the following steps:

[0016] The compound of formula (II) reacts with the compound of formula (III) in the presence of a suitable solvent and a base to obtain a compound of formula (I):

[0017]

[0018] In some embodiments of the present invention, the solvent is formamide.

[0019] In some embodiments of the present invention, the base is triethylamine.

[0020] In some embodiments of the present invention, the reaction temperature is 20-100°C, preferably 50-90°C, and more preferably 70-80°C.

[0021] In some embodiments of the present invention, the reaction time is 4 to 6 hours, preferably 5 hours.

[0022] On the other hand, the present invention further provides a post-processing method, which comprises the following steps:

[0023] 1) Add water to the reaction solution and stir;

[0024] 2) adding an organic solvent to the mixture of step 1, extracting and separating the liquids;

[0025] 3) The organic phase of step 2 is concentrated, crystallized and dried.

[0026] On the other hand, the present invention also provides an HPLC analysis method for detecting impurities of venetoclax, characterized in that:

[0027] 1) Take an appropriate amount of venetoclax test sample, accurately weigh it, add an appropriate amount of methanol to dissolve it, and then dilute it with mobile phase A to a 0.5 mg / ml solution as the test sample solution;

[0028] 2) Take an appropriate amount of pure venetoclax, weigh it accurately, add an appropriate amount of methanol to dissolve it, and then dilute it with mobile phase A to a 0.5 mg / ml solution as reference solution 1;

[0029] 3) Take an appropriate amount of the reference substance of the compound of formula (I), accurately weigh it, add an appropriate amount of methanol to dissolve it, and then dilute it with mobile phase A to a 0.5 mg / ml solution as reference substance solution 2;

[0030] 4) Performing gradient elution on the chromatographic column using mobile phase A and mobile phase B;

[0031] The mobile phase A is trifluoroacetic acid-water, and the mobile phase B is acetonitrile;

[0032] 5) The content of the compound of formula (I) in the venetoclax test sample was calculated using the area normalization method.

[0033] The HPLC analysis method uses mobile phase A and mobile phase B for gradient elution in a certain ratio, and the gradient ratio is:

[0034] 0min, the volume ratio of mobile phase A to mobile phase B is 95:5

[0035] 1min, the volume ratio of mobile phase A to mobile phase B was 95:5

[0036] 10min, the volume ratio of mobile phase A to mobile phase B is 0:100

[0037] 18min, the volume ratio of mobile phase A to mobile phase B was 0:100.

[0038] The beneficial effects of the present invention are:

[0039] The present invention discovers a compound of formula (I), which is reported for the first time and is a completely new compound. The present invention also provides a method for preparing the compound. At the same time, the present invention provides a high performance liquid chromatography gradient method, which can effectively elute and separate the impurity compound of formula (I), so that the peak of the compound of formula (I) is completely separated from the main peak, thereby realizing fast, simple and reliable impurity control of the product. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] Figure 1 : The compound of formula (I)1 H-NMR spectrum

[0041] Figure 2 : Liquid phase spectrum of the compound of formula (I) DETAILED DESCRIPTION

[0042] The following embodiments can enable those skilled in the art to more fully understand the present invention, but the present invention is not limited to the scope of the embodiments.

[0043] Example 1: Preparation of the compound of formula (I)

[0044] 20 ml of formamide, 5.0 g of the compound of formula (II), 2.0 g of the compound of formula (III) and 6.0 g of anhydrous potassium phosphate were added to a 100 ml reaction bottle in sequence, heated to 70-80°C, and stirred for reaction for 5 hours. 100 ml of water and 100 ml of ethyl acetate were added to the reaction solution, stirred and separated, the organic phase was washed with 30 ml of water, concentrated under reduced pressure to obtain an oily substance, 5 ml of ethyl acetate and 25 ml of n-hexane were added, heated and dissolved, stirred and cooled to 10-20°C to precipitate a solid, filtered, and dried with air at 40°C to obtain 2.8 g of the compound of formula (I), with a purity of 99.21% and a yield of 41.5%.

[0045] Example 2: HPLC analysis method

[0046] The liquid phase detection method is determined in accordance with the General Rules 0512 of Part IV of the 2020 edition of the Chinese Pharmacopoeia, and the chromatographic conditions are as follows:

[0047] Chromatographic column: C18, 250×4.6㎜, 5.0μm;

[0048] Mobile phase A: 0.05% trifluoroacetic acid in water

[0049] Mobile phase B: acetonitrile

[0050] Column temperature: 25°C

[0051] Detection wavelength: 220nm

[0052] Flow rate: 1.0ml / min;

[0053] Injection volume: 1 μl

[0054] Mobile phase gradient:

[0055] Time (minutes) Mobile phase A% Mobile phase B% 0.00 95 5 1.00 95 5 10 0.0 100.0 18 0.0 100.0

[0056] The above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention needs to be constantly changed and improved, and these changes and improvements fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.

Claims

1. A method for preparing a venetoclax impurity, wherein the impurity has a structure represented by formula (I): It is characterized in that The following steps are involved: The compound of formula (II) reacts with the compound of formula (III) in the presence of a suitable solvent and a base to obtain the compound of formula (I).

2. The preparation method according to claim 1, characterized in that: The solvent is formamide and the base is triethylamine.

3. The preparation method according to claim 1, characterized in that: The reaction temperature is 20 to 100°C, preferably 50 to 90°C, and more preferably 70 to 80°C.

4. A method for detecting impurities obtained by the method for preparing venetoclax impurities according to claim 1, characterized in that The following steps are involved: 1) Take an appropriate amount of venetoclax test sample, weigh it accurately, add an appropriate amount of methanol to dissolve it, and then dilute it with mobile phase A to 0.5 mg / ml solution as the test solution; 2) Take an appropriate amount of pure venetoclax, weigh it accurately, add an appropriate amount of methanol to dissolve it, and then dilute it with mobile phase A to a 0.5 mg / ml solution as reference solution 1; 3) Take an appropriate amount of the reference substance of the compound of formula (I), accurately weigh it, add an appropriate amount of methanol to dissolve it, and then dilute it with mobile phase A to a 0.5 mg / ml solution as reference substance solution 2; 4) Performing gradient elution on the chromatographic column using mobile phase A and mobile phase B; The mobile phase A is trifluoroacetic acid-water, and the mobile phase B is acetonitrile; 5) The content of the compound of formula (I) in the venetoclax test sample was calculated using the area normalization method.

5. The HPLC analysis method according to claim 4, wherein the mobile phase A and the mobile phase B are used for gradient elution in a certain ratio, wherein the gradient ratio is: 0min, the volume ratio of mobile phase A to mobile phase B is 95:5 1min, the volume ratio of mobile phase A to mobile phase B was 95:5 10min, the volume ratio of mobile phase A to mobile phase B is 0:100 18min, the volume ratio of mobile phase A to mobile phase B was 0:100.